Safety and effectiveness of add on drug pentoxifylline in patients suffering from community acquired pneumonia
- Conditions
- Health Condition 1: J189- Pneumonia, unspecified organism
- Registration Number
- CTRI/2024/08/072499
- Lead Sponsor
- SARANDEV A T V
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Yet Recruiting
- Sex
- Not specified
- Target Recruitment
- 0
1)At least one acute clinical sign compatible with pneumonia (dyspnea, cough, purulent sputum, crackles)
2)Infiltrate on chest X-ray or CT scan suggestive of pneumonia
3)Diagnosis of CAP at or during the 48 hours post-hospital admission.
4)Informed consent signed by the patient, his/her legally authorized representative.
1)Patient on invasive mechanical ventilation.
2)Patients with creatinine clearance less than 30 ml per minute
3)Patient on vasopressors at the time of inclusion
4)Any contraindications to the study drug
5)Patient requiring corticosteroids (except for nebulized corticosteroids) for any reason.
6)Patient treated with antibiotics for more than 7 days prior to admission.
7)Suspicion of aspiration or heath care associated pneumonia.
8)Active tuberculosis
9)On immunosuppressive therapy or malignancy
10)Pregnancy or lactating women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Time to overall clinical stability (TCS) defined as temperature less than or equall to 37·8 degree celsius, heart rate below 100 beats per minute, respiratory rate below 24 breaths per minute, arterial oxygen saturation of 90 percentage or higher on room air, systolic blood pressure of 90 mm Hg or higher, and baseline mental status. TCS is defined as the first day after the starting of study drug all the 5 vital signs fulfill the above criteria on same day and eating and mental status are stable. <br/ ><br> <br/ ><br>Timepoint: Over 7 days
- Secondary Outcome Measures
Name Time Method To evaluate the change in inflammatory markers in terms of change in serum CRP and TNF alpha level between the groups. <br/ ><br>To evaluate the length of hospital stay (LOS) between the groups. <br/ ><br>To evaluate the time to individual vital sign stability between the groups. <br/ ><br>To determine the adverse effects in both the groups.Timepoint: Over the period of study